{"id": "179699", "meta": {"versionId": "9", "lastUpdated": "2024-05-26T19:08:17.473Z", "profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/recommendation"]}, "extension": [{"url": "http://hl7.org/fhir/StructureDefinition/artifact-description", "valueMarkdown": "This example of adapting a Recommendation (removing the A from the end of the Recommendation Statement) shows the use of an Adaptation Profile of ArtifactAssessment and the use of the extensions: artifact-approvalDate, arifact-lastReviewDate, and artifact-effectivePeriod."}, {"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-approvalDate", "valueDate": "2023-11-15"}, {"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-lastReviewDate", "valueDate": "2023-12-01"}, {"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-effectivePeriod", "valuePeriod": {"start": "2024-01-01", "end": "2024-12-31"}}], "url": "https://fevir.net/resources/Composition/179699", "identifier": [{"type": {"text": "FEvIR Object Identifier", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "ACSN", "display": "Accession ID"}]}, "system": "https://fevir.net", "value": "179699", "assigner": {"display": "Computable Publishing LLC"}}], "status": "final", "type": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "Recommendation", "display": "Recommendation"}]}, "date": "2024-05-26T19:08:17.473Z", "author": [{"display": "Joanne Dehnbostel"}], "title": "Recommendation: ADA Obesity Management Recommendation 8.16-adapted", "custodian": {"reference": "Organization/118079", "type": "Organization", "display": "Computable Publishing LLC"}, "relatesTo": [{"type": "derived-from", "classifier": [{"text": "Original Recommendation"}], "resourceReference": {"reference": "Composition/179466", "type": "Composition", "display": "Recommendation: ADA Obesity Management Recommendation 8.16"}}, {"type": "derived-from", "classifier": [{"text": "Adaptation Report"}], "resourceReference": {"reference": "ArtifactAssessment/179698", "type": "ArtifactAssessment", "display": "Joanne Dehnbostel's Adaptation Report of Recommendation: ADA Obesity Management Recommendation 8.16"}}], "resourceType": "Composition", "section": [{"title": "Recommendation Specification", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "recommendation-specification", "display": "Recommendation Specification"}], "text": "Recommendation Specification"}, "section": [{"title": "Recommendation Statement", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "recommendation-statement", "display": "Recommendation Statement"}], "text": "overallSummary"}, "text": {"status": "additional", "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">8.16 Metabolic surgery should be a recommended option to treat type 2 diabetes in screened surgical candidates with BMI \u226540 kg/m2 (BMI \u226537.5 kg/m2 in Asian Americans) and in adults with BMI 35.0\u201339.9 kg/m2 (32.5\u201337.4 kg/m2 in Asian Americans) who do not achieve durable weight loss and improvement in comorbidities (including hyperglycemia) with nonsurgical methods.</div>"}, "entry": [{"reference": "ArtifactAssessment/179469", "type": "ArtifactAssessment"}]}, {"title": "Recommendation Ratings", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "ratings", "display": "Ratings"}], "text": "overallRatings"}, "text": {"status": "generated", "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">A</div>"}, "entry": [{"reference": "ArtifactAssessment/179469", "type": "ArtifactAssessment"}]}, {"title": "Population", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "population", "display": "Population"}], "text": "population"}, "text": {"status": "generated", "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Inclusion Criteria: [[1]] Adults. [[2]] Diagnosed with type 2 diabetes. [[3]] Body Mass Index (BMI) \u2265 40.0 kg/m2 (BMI \u2265 37.5 kg/m2 in Asian Americans), or BMI \u2265 35.0 kg/m2 and \u2264 39.9 kg/m2 (BMI 32.5-37.4 kg/m2 in Asian Americans) who do not achieve durable weight loss and improvement in comorbidities (including hyperglycemia) with nonsurgical methods. [[4]] Screened surgical candidates.</div>"}, "entry": [{"reference": "Group/32139", "type": "Group", "display": "RecommendationEligibilityCriteria: Eligibility Criteria for Bariatric Surgery (ADA Recommendation 8.16)"}]}, {"title": "Action", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "action", "display": "Action"}], "text": "action"}, "text": {"status": "generated", "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Metabolic surgery is recommended.</div>"}, "entry": [{"reference": "PlanDefinition/179468", "type": "PlanDefinition", "display": "PlanDefinition for Recommendation: ADA Obesity Management Recommendation 8.16"}]}, {"title": "Opposite Action", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "opposite-action", "display": "Opposite Action"}], "text": "oppositeAction"}, "emptyReason": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/list-empty-reason", "code": "notstarted", "display": "Not Started"}]}}]}, {"title": "Discussion", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "discussion", "display": "Discussion"}]}, "emptyReason": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/list-empty-reason", "code": "notstarted", "display": "Not Started"}]}}, {"title": "Evidence", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "evidence", "display": "Evidence"}], "text": "Evidence"}, "text": {"status": "generated", "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">ADA Level of Evidence A. A substantial body of evidence has now been accumulated, including data from numerous randomized controlled (nonblinded) clinical trials, demonstrating that metabolic surgery achieves superior glycemic control and reduction of cardiovascular risk factors in patients with type 2 diabetes and obesity compared with various lifestyle/medical interventions.</div>"}, "entry": [{"reference": "ArtifactAssessment/179469", "type": "ArtifactAssessment"}]}, {"title": "Justification", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "justification", "display": "Justification"}], "text": "Justification"}, "emptyReason": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/list-empty-reason", "code": "notstarted", "display": "Not Started"}]}}, {"title": "Considerations", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "considerations", "display": "Considerations"}], "text": "Considerations"}, "section": [{"title": "Overall Considerations Summary", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "summary", "display": "Summary"}], "text": "overallConsiderationsSummary"}, "emptyReason": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/list-empty-reason", "code": "notstarted", "display": "Not Started"}]}}, {"title": "Subgroup Considerations Summary", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "subgroup-considerations", "display": "Subgroup Considerations"}], "text": "subgroupConsiderationsSummary"}, "emptyReason": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/list-empty-reason", "code": "notstarted", "display": "Not Started"}]}}, {"title": "Implementation Considerations Summary", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "implementation-considerations", "display": "Implementation Considerations"}], "text": "implementationConsiderationsSummary"}, "emptyReason": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/list-empty-reason", "code": "notstarted", "display": "Not Started"}]}}, {"title": "Monitoring Considerations Summary", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "monitoring-considerations", "display": "Monitoring Considerations"}], "text": "monitoringConsiderationsSummary"}, "emptyReason": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/list-empty-reason", "code": "notstarted", "display": "Not Started"}]}}, {"title": "Competing Interests Summary", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "competing-interests", "display": "Competing Interests"}], "text": "competingInterestsSummary"}, "text": {"status": "generated", "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">All members of the PPC are required to disclose potential conflicts of interest with industry and other relevant organizations. These disclosures are discussed at the outset of each Standards of Care revision meeting. Members of the committee, their employers, and their disclosed conflicts of interest are listed in 'Disclosures: Standards of Medical Care in Diabetes\u20142021' (https://doi.org/10.2337/dc21-SPPC). The ADA funds development of the Standards of Care out of its general revenues and does not use industry support for this purpose. NOTE: The disclosed conflicts of interest was not found at the suggested URL</div>"}, "entry": [{"reference": "ArtifactAssessment/179469", "type": "ArtifactAssessment"}]}, {"title": "Research Priorities Summary", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "research-considerations", "display": "Research Considerations"}], "text": "researchConsiderationsSummary"}, "emptyReason": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/list-empty-reason", "code": "notstarted", "display": "Not Started"}]}}]}]}